Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476446 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL1476965 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL1477046 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL1477320 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL1477480 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4 | |
| SCHEMBL1477711 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL1477360 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL1476406 | 0.76 | GRM5 (0.55) | GRM5APPCHRNB2CHRNA4MAPT | |
| SCHEMBL16289453 | 0.75 | GRM5 (0.30) | GRM5 | |
| Hydrochloric Acid SCHEMBL1477130 | 0.74 | GRM5 (0.53) | GRM5APPCHRNB2CHRNA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551844-B1 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR SAU (ES) | 2010-07-28 | — | — | EP | disclosed |
| EP-2138496-A1 | Antitumoral analogs of lamellarins | Pharma Mar, S.A.U. (ES) | 2009-12-30 | — | — | EP | disclosed |
| US-7396837-B2 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2008-07-08 | — | — | US | disclosed |
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2006-08-03 | — | — | US | disclosed |
| EP-1551844-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | Pharma Mar, S.A.U. (ES) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004014917-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR, S.A.U. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PLIN3, LPAR3, LPAR2 | GRM5 4530/4885APP 4360/4885CHRNB2 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.